Apolipoprotein A1 and high-density lipoprotein limit low-density lipoprotein transcytosis by binding SR-B1

Karen Y Y Fung1, Tse Wing Winnie Ho2, Zizhen Xu3

  • 1Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada; Keenan Research Centre, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada.

PubMed

Insights

High-density lipoprotein (HDL) may protect against atherosclerosis by competing with low-density lipoprotein (LDL) for binding to scavenger receptor B1 (SR-B1), thus reducing LDL deposition in arteries.

Area of Science:

  • Cardiovascular Biology
  • Lipid Metabolism
  • Atherosclerosis Research

Background:

  • Atherosclerosis involves low-density lipoprotein (LDL) deposition and oxidation in arteries, leading to occlusion.
  • Transcytosis of LDL across endothelial cells is a key step in atherosclerosis development.
  • High-density lipoprotein (HDL) is believed to offer protection against atherosclerosis.

Purpose of the Study:

  • To investigate whether apolipoprotein A1 (APOA1), a component of HDL, can compete with LDL for scavenger receptor B1 (SR-B1) binding.
  • To determine if HDL or APOA1 can inhibit LDL transcytosis and subsequent deposition in the arterial wall.

Main Methods:

  • In vitro studies using coronary endothelial cells to quantify fluorescent LDL internalization and transcytosis.
  • Microscale thermophoresis and affinity capture assays to assess interactions between SR-B1 and APOA1.
  • In vivo experiments in male mice to evaluate the effect of increased HDL or APOA1 levels on LDL deposition.

Main Results:

  • SR-B1 and APOA1 were found to interact, with enhanced binding observed for the APOA1-Milano variant.
  • Increased HDL levels in mice reduced the acute deposition of fluorescent LDL in the aorta.
  • Both wild-type APOA1 and APOA1-Milano inhibited LDL deposition, with APOA1-Milano showing a more potent effect.

Conclusions:

  • HDL, through APOA1, may limit LDL transcytosis by competing for SR-B1 binding.
  • This competition potentially reduces LDL deposition in the sub-arterial space, contributing to HDL's atheroprotective role.
  • APOA1-Milano demonstrates a stronger inhibitory effect on LDL deposition compared to wild-type APOA1.

Related Concept Videos

Receptor-mediated Endocytosis01:39

Receptor-mediated Endocytosis

Overview
104.4K
Drug Binding to Blood Components01:30

Drug Binding to Blood Components

When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
148
Regulation of Nuclear Protein Sorting01:45

Regulation of Nuclear Protein Sorting

Nuclear protein sorting regulates nucleus composition and gene expression, crucial for determining the fate of a eukaryotic cell. Hence, the entry and exit of molecules across the nuclear envelope is a tightly controlled process. Nuclear protein sorting can be inhibited by one of the following ways: 1) masking cargo signal sequences, 2) modifying the nuclear receptor's affinity for cargo, 3) controlling the nuclear pore size, 4) retaining the cargo during its transit to the cytosol or the...
2.4K
Factors Affecting Protein-Drug Binding: Drug-Related Factors01:18

Factors Affecting Protein-Drug Binding: Drug-Related Factors

Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
99
Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

Factors Affecting Protein-Drug Binding: Protein-Related Factors

Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
156
Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
5.6K